RxDoctor Payments Data

Francisca Paz, APRN

Nurse Practitioner · San Antonio, TXNPI 1992325682

Payments from drug & device makers

$10,562in general payments, 2019–2025

Across 290 payments — averaging $36.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • AstraZeneca$1K
  • Merck$761
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$753
  • Novartis$703
  • Boehringer Ingelheim$425
  • plus $3K from 28 others

What the payments were for

  • Travel & lodging$2,04219%
  • Food & beverage$8,44480%
  • Education$761%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,562 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$1,396
Medicare patients
13
Services billed
19

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban68$55,986
XareltoRivaroxaban21$25,742
Nebivolol Hcl15$843
Valsartan23$772
Rosuvastatin Calcium55$738
Telmisartan11$526
Nifedipine ErNifedipine17$481
Losartan Potassium58$457
Isosorbide Mononitrate ErIsosorbide Mononitrate15$385
Metoprolol Tartrate57$366
Metoprolol Succinate37$348
Olmesartan Medoxomil19$303
Atorvastatin Calcium42$298
Lisinopril34$262
Diltiazem 24hr Er (Cd)Diltiazem Hcl11$226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$383$55,98668 claims
Johnson & JohnsonXarelto$259$25,74221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →